This retrospective study evaluated the efficacy of adding anti-PD1/L1 or anti-VEGF therapy to platinum-based chemotherapy in EGFR-TKI-resistant EGFR-mutant adenocarcinoma patients in a single center and real-world setting. Here, EGFR is linked to adenocarcinoma.